X

Drug Profile

Research programme: siRNA diabetes therapy - Alnylam Pharmaceuticals

Latest Information Update: 16 May 2014

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sirna Therapeutics
Class Nucleotides; RNA
Mechanism of Action RNA inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Type 2 diabetes mellitus

Most Recent Events

06 Mar 2014 Alnylam Pharmaceuticals acquires Sirna Therapeutics
18 Jan 2008 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com